

06 February 2023

## Biologic medicines in Dermatology

Q1. How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira **49**
- Adalimumab Biosimilar **181**
- Apremilast **7**
- Bimekizumab **<5**
- Brodalumab **<5**
- Certolizumab **<5**
- Dimethyl fumarate **<5**
- Etanercept – Enbrel **<5**
- Etanercept Biosimilar **9**
- Guselkumab **86**
- Infliximab – Remicade **5**
- Infliximab Biosimilar **8**
- Ixekizumab **50**
- Risankizumab **74**
- Secukinumab **42**
- Tildrakizumab **6**
- Ustekinumab **79**

Q2. How many patients were treated in the last 3 months by the **Dermatology** department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

- Adalimumab – Humira **20**
- Adalimumab Biosimilar **17**
- Infliximab – Remicade **<5**
- Infliximab Biosimilar **<5**
- Secukinumab **<5**
- Ustekinumab **<5**

Q3. How many patients were treated in the last 3 months by the **Dermatology** department for Psoriasis ONLY in the last three months with the following:

- Ciclosporin
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

**As there is no comprehensive database for Dermatology, collation of this information would take more than 18 hours due to the complexity of retrieving the data. This would exceed the costs limit specified in the FOI Act**

**06 February 2023**

**We estimate that compliance with this element of the request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.**